NovoCure Can Recover On Its Long-Term Outlook

  • NovoCure’s growth has stalled as their GBM market share has gone to 35%-40%, but GBM still offers several additional growth opportunities.
  • Then there are the 4 P3 trials which, if successful, could add additional cancer treatments and dramatically expand the TAM.
  • That’s two years out, but the company generates and has plenty of cash to keep at it.
  • The shares have come down significantly but that’s no surprise given the low growth and market mayhem.
  • The shares are still far from cheap, although in two years’ time the company’s prospects could very well be dramatically better, so this is for the patient investor.
  • Looking for more investing ideas like this one? Get them exclusively at SHU Growth Portfolio. Learn More »

NovoCure Stock: Can Recover On Its Long-Term Outlook (NASDAQ:NVCR)